Justin Walsh
Stock Analyst at Jones Trading
(3.40)
# 977
Out of 5,182 analysts
40
Total ratings
45.95%
Success rate
24.11%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Buy | $49 → $44 | $22.78 | +93.15% | 2 | Apr 2, 2026 | |
| NMTC NeuroOne Medical Technologies | Initiates: Buy | $1.5 | $0.73 | +105.00% | 1 | Mar 2, 2026 | |
| LNTH Lantheus Holdings | Downgrades: Hold | n/a | $80.59 | - | 11 | Feb 27, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $16 | $3.64 | +339.56% | 1 | Dec 23, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $83 | $316.14 | -73.75% | 1 | Sep 18, 2025 | |
| VNRX VolitionRx | Initiates: Buy | $3 | $0.17 | +1,709.41% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $2.29 | +424.02% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $6.11 | +391.00% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $56.08 | - | 1 | Apr 2, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $1.98 | +455.56% | 1 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $34.17 | +22.91% | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $4.47 | +392.17% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.22 | +279.15% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.49 | +473.07% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $0.61 | +555.74% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.43 | +483.09% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360 | $15.47 | +2,227.08% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $4.80 | +38,962.50% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $35.93 | -44.34% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $0.50 | +39,908.00% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.17 | +93.42% | 1 | Jan 19, 2022 |
Alto Neuroscience
Apr 2, 2026
Maintains: Buy
Price Target: $49 → $44
Current: $22.78
Upside: +93.15%
NeuroOne Medical Technologies
Mar 2, 2026
Initiates: Buy
Price Target: $1.5
Current: $0.73
Upside: +105.00%
Lantheus Holdings
Feb 27, 2026
Downgrades: Hold
Price Target: n/a
Current: $80.59
Upside: -
AtaiBeckley
Dec 23, 2025
Initiates: Buy
Price Target: $16
Current: $3.64
Upside: +339.56%
Praxis Precision Medicines
Sep 18, 2025
Initiates: Buy
Price Target: $83
Current: $316.14
Upside: -73.75%
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $0.17
Upside: +1,709.41%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $2.29
Upside: +424.02%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $6.11
Upside: +391.00%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $56.08
Upside: -
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $1.98
Upside: +455.56%
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $34.17
Upside: +22.91%
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $4.47
Upside: +392.17%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $4.22
Upside: +279.15%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $3.49
Upside: +473.07%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.61
Upside: +555.74%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $3.43
Upside: +483.09%
May 16, 2023
Initiates: Buy
Price Target: $360
Current: $15.47
Upside: +2,227.08%
Oct 7, 2022
Initiates: Buy
Price Target: $1,875
Current: $4.80
Upside: +38,962.50%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $35.93
Upside: -44.34%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $0.50
Upside: +39,908.00%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $5.17
Upside: +93.42%